Q-omics provides the consensus-scored TRIM80P profile across patient tissues and cancer cell-line models. TRIM80P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TRIM80P is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, TRIM80P RNA expression shows 11,305 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BRCA, THCA, and KIRP as cancer lineages where TRIM80P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM80P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM80P survival associations across molecular data types. TRIM80P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM80P RNA expression–survival associations across cancer types. High TRIM80P expression shows unfavorable associations in LGG, ACC and DLBC, but favorable associations in BRCA, LUAD and LIHC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for TRIM80P RNA expression.
This table summarizes TRIM80P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM80P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM80P shows lower tumor expression in THCA, KICH, LUSC, LUAD, CHOL and KIRC. The THCA box plot shows higher TRIM80P RNA expression in normal versus tumor tissue (log2 FC = −0.081, t-test p < 0.001).
This table shows molecular features associated with TRIM80P in patient tissues and cancer cell lines. In patient samples, TRIM80P shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
